STING1 and ovarian neoplasm: Findings from our study stronglysuggest that HGSC patients can significantly benefit from treatment with STINGagonist to enhance anti-tumour immune response or overcome adaptive immuneresistance, via enhanced CD8+ TIL cross-priming postchemotherapy, when administered selectively in patients with an under-reactive TME.Since ovarian tumours responded poorly to immune checkpoint blockade, findings fromour will be foundational to the design of treatment strategies that can potentiallycombine STING agonist to enhance response.